All In Biotech

Drug Trial Radar · NCT06868199

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

87

Planned (sponsor's estimate)

Start

May 6, 2025

Primary completion

Aug 1, 2027

Study completion Feb 1, 2028

Sponsor

Lead sponsor
LaNova Medicines LimitedIndustry
Sponsor type
Industry
First posted
Mar 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For phase I ,this study is to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D) and/or Maximum Tolerated Dose (MTD) for LM-168 as a single agent or in combination with toripalimab in subjects with advanced solid tumours. For phase II ,this study is to assess the preliminary anti-tumour activity of LM-168 as a single agent or in combination with toripalimab measured by objective response rate (ORR) in subjects with advanced solid tumours.

Conditions

  • Advanced Solid Tumours

Interventions

  • LM-168Drug

    Q3W,Intravenous Drip

  • ToripalimabDrug

    Q3W,Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: 78 weeks
  2. Incidence of dose-limitingtoxicity (DLT)Time frame: 78 weeks
  3. Incidence of serious adverse event (SAE)Time frame: 78 weeks
  4. Temperature (Celsius)Time frame: 78 weeks
  5. Pulse in BPM(Beat per Minute)Time frame: 78 weeks
  6. Blood Pressure in mmHgTime frame: 78 weeks
  7. Weight in KgTime frame: 78 weeks
  8. Height in centimeterTime frame: 78 weeks
  9. Blood Routine examinationTime frame: 78 weeks
  10. Urine Routine testTime frame: 78 weeks
  11. Blood biochemistry testTime frame: 78 weeks
  12. Coangulation function testTime frame: 78 weeks
  13. Thyroid function testTime frame: 78 weeks
  14. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentageTime frame: 78 weeks
  15. 12-lead electrocardiogram (ECG) in HRTime frame: 78 weeks
  16. 12-lead electrocardiogram (ECG) in RRTime frame: 78 weeks
  17. 12-lead electrocardiogram (ECG) in PRTime frame: 78 weeks
  18. 12-lead electrocardiogram (ECG) in QRSTime frame: 78 weeks
  19. 12-lead electrocardiogram (ECG) in QTTime frame: 78 weeks
  20. 12-lead electrocardiogram (ECG) in QTcFTime frame: 78 weeks
  21. ECOG(Eastern Cooperative Oncology Group) scoreTime frame: 78 weeks
  22. Objective Response Rate (ORR)Time frame: From 78th week to 130th week (52 weeks in total)

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Macquarie University

    Ryde, New South Wales, Australia · Recruiting

  • MUPharm Pty Limited trading as Macquarie University Hospital Parmarcy

    Ryde, New South Wales, Australia · Recruiting

  • Cancer Care Wollongong Pty Limited

    Wollongong, New South Wales, Australia · Recruiting

  • Bayview Health-Investigational Drug Services

    Perth, Western Australia, Australia · Recruiting

  • One Clinical Reasearch

    Perth, Western Australia, Australia · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.